Cycloset (Quick-Release Bromocriptine Mesylate), a Novel Centrally Acting Treatment for Type 2 Diabetes

Abstract

Young adulthood is a time of change when diabetes control often deteriorates. Prior to 2002, 40% of young people with diabetes in our region did not attend specialist clinics, precipitating the establishment of a purpose-designed transition clinic. This study reviewed the efficacy of the young adult clinic over the last three years. Up to October 2007, ninety-three young people had attended the clinic (51 male, age 21.2(18-24) years, diabetes duration 10.8±0.5 years). Two patients had Type 2 diabetes (on oral hypoglycaemic agents) and 64 (69%) were on multiple daily injections of insulin. Mean HbA1c was 9.3±0.2% with 18 (19%) achieving a target HbA1c <7.5%. Over the study period, 522 clinic appointments were made with 437 (84%) attended, 20 (4%) cancelled by the patient and 65 (12%) not attended. Four patients moved from the area. Among the 89 remaining patients, 74 (83%) attended for annual review in the previous fifteen months, with 69 (78%) undergoing digital retinal screening, 71 (80%) foot surveillance, and 52 (58%) providing a urine sample for microalbuminuria. Among those screened, prevalence of retinopathy (any grade) was 45% and microalbuminuria 10%. Although glycaemic control is sub-optimal for the majority of young adults, the establishment of a transition clinic has improved attendance and resulted in high rates of screening for complications. Determination of microalbuminuria remains problematic, requiring the patient to supply a urine sample and alternative biomarkers may be of benefit in this population. Cycloset (Quick-Release Bromocriptine Mesylate), a Novel Centrally Acting Treatment for Type 2 Diabetes ANTHONY H CINCOTTA, J MICHAEL GAZIANO, MICHAEL EZROKHI , RICHARD E SCRANTON Veroscience, Tiverton, RI, Harvard Medical School, Boston, MA,